The ' Extremely Positive ' Results That Helped Roivant Leapfrog Its 50-Day Line, Nearing A Breakout

Roivant stock is nearing a breakout Tuesday after the biotech company announced positive results in an eye-disease study and a $1.5 billion share repurchase. The company enrolled 26 patients with noninfectious uveitis, a condition that causes inflammation in one or both eyes. Roivant Sciences…#roivantsciences #leerinkpartners #davidrisinger #humira #abbvie #mattgline #allisongatlin #ibdagatlin

Source: Reuters: Health - April 3, 2024 Category: Consumer Health News Source Type: news